- Home
- OCSL vs PCRX Comparison
OCSL vs PCRX Comparison
Compare OCSL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCSL
- PCRX
- Stock Information
- Founded
- OCSL 2007
- PCRX 2006
- Country
- OCSL United States
- PCRX United States
- Employees
- OCSL N/A
- PCRX N/A
- Industry
- OCSL Finance: Consumer Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- OCSL Finance
- PCRX Health Care
- Exchange
- OCSL Nasdaq
- PCRX Nasdaq
- Market Cap
- OCSL 1.1B
- PCRX 1.2B
- IPO Year
- OCSL 2008
- PCRX 2011
- Fundamental
- Price
- OCSL $12.93
- PCRX $22.27
- Analyst Decision
- OCSL Hold
- PCRX Buy
- Analyst Count
- OCSL 6
- PCRX 5
- Target Price
- OCSL $15.20
- PCRX $32.40
- AVG Volume (30 Days)
- OCSL 873.5K
- PCRX 494.3K
- Earning Date
- OCSL 11-18-2025
- PCRX 11-05-2025
- Dividend Yield
- OCSL 12.38%
- PCRX N/A
- EPS Growth
- OCSL N/A
- PCRX N/A
- EPS
- OCSL 0.55
- PCRX N/A
- Revenue
- OCSL $334,099,000.00
- PCRX $705,848,000.00
- Revenue This Year
- OCSL N/A
- PCRX $7.36
- Revenue Next Year
- OCSL N/A
- PCRX $10.07
- P/E Ratio
- OCSL $23.64
- PCRX N/A
- Revenue Growth
- OCSL N/A
- PCRX 2.25
- 52 Week Low
- OCSL $12.44
- PCRX $15.92
- 52 Week High
- OCSL $16.66
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- OCSL 44.79
- PCRX 24.75
- Support Level
- OCSL $12.44
- PCRX $24.31
- Resistance Level
- OCSL $12.73
- PCRX $26.05
- Average True Range (ATR)
- OCSL 0.23
- PCRX 0.77
- MACD
- OCSL -0.01
- PCRX -0.39
- Stochastic Oscillator
- OCSL 66.14
- PCRX 5.76
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.